Journal of Clinical Epidemiology
Journal
-
- Overview
-
- Identity
-
- View All
-
Overview
publication venue for
-
An international survey indicated that unpublished systematic reviews exist
2009
-
Importance of pre-release and fast-track publications
2000
-
“Cumulative meta analysis of clinical trials builds evidence for exemplary medical care”: Discussion
1995
-
The social science contribution to pharmacoepidemiology
1991
-
CROSS-CULTURAL ADAPTATION AND VALIDATION TO SPANISH OF THE PANELVIEW INSTRUMENT TO EVALUATE THE HEALTH GUIDELINES DEVELOPMENT PROCESS..
111569.
2024
-
Characteristics, consent patterns, and challenges of randomized trials using the Trials within Cohorts (TwiCs) design - A scoping review.
174:111469-111469.
2024
-
Corrigendum to "Development of an international glossary for clinical guidelines collaboration" "[Journal of Biomechanics 158 (2023) 84-91]"..
111514.
2024
-
Simultaneous evaluation of the imprecision and inconsistency domains of GRADE can be performed using prediction intervals..
175:111543.
2024
-
Resource use and costs of investigator-sponsored randomized clinical trials in Switzerland, Germany, and the United Kingdom: a metaresearch study..
176:111536.
2024
-
Network meta-analysis: a powerful tool for clinicians, decision-makers, and methodologists..
176:111537.
2024
-
Corrigendum to 'Pilot and feasibility trials in surgery are incompletely reported according to the CONSORT checklist: a meta-research study' [Journal of Clinical Epidemiology 170 (2024)]..
111510.
2024
-
A systematic survey of 200 systematic reviews with network meta-analysis (published 2020–2021) reveals that few reviews report structured evidence summaries.
173:111445-111445.
2024
-
Panel stacking is a threat to consensus statement validity.
173:111428-111428.
2024
-
Required knowledge for guideline panel members to develop healthcare related testing recommendations: a developmental study.
173:111438-111438.
2024
-
A call for caution when using network methods to study multimorbidity: an illustration using data from the Canadian Longitudinal Study on Aging.
172:111435-111435.
2024
-
Barriers and opportunities faced by public health practitioners in using public health guidance on COVID-19: a knowledge translation exercise for the eCOVID-19 RecMap.
172:111410-111410.
2024
-
GRADE Guidance 39: Using GRADE-ADOLOPMENT to adopt, adapt or create contextualized recommendations from source guidelines and evidence syntheses.
174:111494-111494.
2024
-
Journal requirement for data sharing statements in clinical trials: a cross-sectional study.
172:111405-111405.
2024
-
Physicians found an interactive tool displaying structured evidence summaries for multiple comparisons understandable and useful: a qualitative user testing study.
172:111399-111399.
2024
-
The impact of an online course on agreement rates of the certainty of evidence assessment using Grading of Recommendations, Assessment, Development, and Evaluation Approach: a before-and-after study.
172:111407-111407.
2024
-
A method was developed for correcting the bias in the usual study weights in meta-analyses: author’s reply.
171:111358-111358.
2024
-
Guideline for reporting systematic reviews of outcome measurement instruments (OMIs): PRISMA-COSMIN for OMIs 2024.
173:111422-111422.
2024
-
Latin American Panelists find GRADE-ADOLOPMENT useful and important to contextualize recommendations in their region.
175:111483-111483.
2024
-
Reporting of health equity considerations in vaccine trials for COVID-19: author’s reply.
171:111374-111374.
2024
-
Values and preferences in COVID-19 public health guidelines: A systematic review.
174:111473-111473.
2024
-
GRADE concept paper 8: judging the certainty of discrimination performance estimates of prognostic models in a body of validation studies.
170:111344-111344.
2024
-
Pilot and feasibility trials in surgery are incompletely reported according to the CONSORT checklist: a meta-research study.
170:111335-111335.
2024
-
Core outcome set developers should consider and specify the level of granularity of outcome domains.
169:111307-111307.
2024
-
Reporting of health equity considerations in vaccine trials for COVID-19: a methodological review.
169:111315-111315.
2024
-
Representation of published core outcome sets in practice guidelines.
169:111311-111311.
2024
-
The GRADE Working Group and CINeMA approaches provided inconsistent certainty of evidence ratings for a network meta-analysis of opioids for chronic noncancer pain.
169:111276-111276.
2024
-
The role of scoping reviews in guideline development.
169:111301-111301.
2024
-
Grilling the data: application of specification curve analysis to red meat and all-cause mortality.
168:111278-111278.
2024
-
Methods proposed for monitoring the implementation of evidence-based research: a cross-sectional study.
168:111247-111247.
2024
-
Motivations for investigating health inequities in observational epidemiology: a content analysis of 320 studies.
168:111283-111283.
2024
-
Conduct and reporting of multivariate network meta-analyses: a scoping review.
166:111238-111238.
2024
-
GRADE Concept 7: Issues and Insights Linking Guideline Recommendations to Trustworthy Essential Medicine Lists.
166:111241-111241.
2024
-
Guideline panel social dynamics influence the development of clinical practice recommendations: a mixed-methods systematic review.
166:111224-111224.
2024
-
Searching a methods topic: practical challenges and implications for search design.
166:111201-111201.
2024
-
A multimethods randomized trial found that plain language versions improved adults understanding of health recommendations.
165:111219-111219.
2024
-
A scoping review reveals candidate quality indicators of knowledge translation and implementation science practice tools.
165:111205-111205.
2024
-
Clinical judgment shows similar and sometimes superior discrimination compared to prognostic clinical prediction models: a systematic review.
165:111200-111200.
2024
-
Compelling evidence from meta-epidemiological studies demonstrates overestimation of effects in randomized trials that fail to optimize randomization and blind patients and outcome assessors.
165:111211-111211.
2024
-
GRADE guidance 37: rating imprecision in a body of evidence on test accuracy.
165:111189-111189.
2024
-
Operationalizing the GRADE-equity criterion to inform guideline recommendations: application to a medical cannabis guideline.
165:111185-111185.
2024
-
GRADE GUIDANCE 38: Updated guidance for rating up certainty of evidence due to a dose-response gradient.
164:45-53.
2023
-
International variation in ethics and contract approval processes for a low-risk observational study of mechanical ventilation discontinuation practices.
164:27-34.
2023
-
The design of studies testing the effectiveness of risk-guided care has many challenges: a scoping review addressing key considerations.
164:15-26.
2023
-
GRADE concept 6: a novel application of external indirect evidence into GRADE ratings of evidence certainty in network meta-analysis.
163:95-101.
2023
-
GRADE guidance 23: considering cost-effectiveness evidence in moving from evidence to health-related recommendations.
162:135-144.
2023
-
Prospective collaborative recommendation development: a novel model for more timely and trustworthy guidelines.
162:156-159.
2023
-
Using evidence to decision frameworks led to guidelines of better quality and more credible and transparent recommendations.
162:38-46.
2023
-
A multimethods randomized trial found that plain language versions improved parents’ understanding of health recommendations.
161:8-19.
2023
-
A novel framework for incorporating patient values and preferences in making guideline recommendations: guideline panel surveys.
161:164-172.
2023
-
Equity issues rarely addressed in the development of COVID-19 formal recommendations and good practice statements: a cross-sectional study.
161:116-126.
2023
-
Guidance needed: where should randomized studies which do not assess a health outcome be registered?.
161:183-184.
2023
-
Heterogeneous methodology in the development of patient versions of clinical practice guidelines: a scoping review.
161:53-64.
2023
-
Noninferiority margins exceed superiority effect estimates for mortality in cardiovascular trials in high-impact journals.
161:20-27.
2023
-
Qualitative study of guideline panelists: innovative surveys provided valuable insights regarding patient values and preferences.
161:173-180.
2023
-
A new taxonomy is proposed for defining the interests of stakeholders’ representatives in health research: the case of guideline development.
160:147-150.
2023
-
A scoping review establishes need for consensus guidance on reporting health equity in observational studies.
160:126-140.
2023
-
Grading of recommendations assessment, development, and evaluation concept article 5: addressing intransitivity in a network meta-analysis.
160:151-159.
2023
-
Trials using composite outcomes neglect the presence of competing risks: a methodological survey of cardiovascular studies.
160:1-13.
2023
-
Corrigendum to methodological approaches for developing, reporting, and assessing evidence-based clinical practice guidelines: a systematic survey [Journal of Clinical Epidemiology 146 (2022) 77-85].
159:354-355.
2023
-
GRADE concept 4: rating the certainty of evidence when study interventions or comparators differ from PICO targets.
159:40-48.
2023
-
The BIGG-REC database makes available all WHO/PAHO evidence informed recommendations.
159:257-265.
2023
-
The development methods of official GRADE articles and requirements for claiming the use of GRADE – A statement by the GRADE guidance group.
159:79-84.
2023
-
CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomized trials.
158:149-165.
2023
-
Development of an international glossary for clinical guidelines collaboration.
158:84-91.
2023
-
GRADE guidance 36: updates to GRADE's approach to addressing inconsistency.
158:70-83.
2023
-
Presentation approaches for enhancing interpretability of patient-reported outcomes in meta-analyses: a systematic survey of Cochrane reviews.
158:119-126.
2023
-
Reporting standards for child health research were few and poorly implemented.
158:141-148.
2023
-
An extension minimal important difference credibility item addressing construct proximity is a reliable alternative to the correlation item.
157:46-52.
2023
-
Heterogeneity across outcomes reported in clinical trials for older adults with depression: a systematic survey.
157:59-73.
2023
-
Methodology and design of platform trials: a meta-epidemiological study.
157:1-12.
2023
-
The impact of climate change on health needs structured evidence assessment and an evidence to action framework to make decisions: a proposal to adopt the GRADE approach.
157:146-153.
2023
-
Conceptualizing the reporting of living systematic reviews.
156:113-118.
2023
-
Response rates in email vs. mail surveys for urologists: a randomized controlled trial.
156:123-124.
2023
-
Sponsorship bias in oncology cost effectiveness analysis.
156:22-29.
2023
-
The life and death of living systematic reviews: a methodological survey.
156:11-21.
2023
-
Methods for living guidelines: early guidance based on practical experience. Paper 1: Introduction.
155:84-96.
2023
-
Methods for living guidelines: early guidance based on practical experience. Paper 3: selecting and prioritizing questions for living guidelines.
155:73-83.
2023
-
Methods for living guidelines: early guidance based on practical experience. Paper 4: search methods and approaches for living guidelines.
155:108-117.
2023
-
Methods for living guidelines: early guidance based on practical experience. Paper 5: decisions on methods for evidence synthesis and recommendation development for living guidelines.
155:118-128.
2023
-
A call for error management in academic clinical research.
154:208-211.
2023
-
Challenges with need to improve the reference standard in diagnosis paper 4: response to reed.
154:218-218.
2023
-
Challenges with need to improve the reference standard in diagnosis: paper 2: real-world case examples from GRADE for when a reference standard is not clearly defined/ easily replicable or when it is infeasible/ unethical to perform the reference standard.
154:206-207.
2023
-
Decision criteria for selecting essential medicines and their connection to guidelines: an interpretive descriptive qualitative interview study.
154:146-155.
2023
-
Improving grading of recommendations assessment, development, and evaluation evidence tables part 4: a three-arm noninferiority randomized trial demonstrates improved understanding of content in summary of findings tables with a new format.
154:125-135.
2023
-
The GIN-McMaster guideline tool extension for the integration of quality improvement and quality assurance in guidelines: a description of the methods for its development.
154:197-203.
2023
-
The Global Evidence Commission's report provided a wake-up call for the evidence community.
154:212-215.
2023
-
Heterogeneity in multicentre trial participating centers: lessons from the TOPCAT trial on interpreting trial data for clinical practice.
153:78-82.
2023
-
A method was developed for correcting the bias in the usual study weights in meta-analyses.
152:23-29.
2022
-
Case studies to explore the optimal use of randomized and nonrandomized studies in evidence syntheses that use GRADE.
152:56-69.
2022
-
Encounter-based randomization did not result in contamination in a shared decision-making trial: a secondary analysis.
152:185-192.
2022
-
Evidence, values, and masks for control of COVID-19: 2 years later.
152:298-299.
2022
-
Instruments assessing risk of bias of randomized trials frequently included items that are not addressing risk of bias issues.
152:218-225.
2022
-
Strong and high-quality evidence synthesis needs Cochrane: a statement of support by the GRADE Guidance Group.
152:285-287.
2022
-
Update of the agency for healthcare research and quality guidance on using nonrandomized studies in evidence syntheses.
152:307-308.
2022
-
A systematic review shows minimal evidence for measurement properties of psychological functioning outcomes in whiplash.
151:29-44.
2022
-
Resources supporting trustworthy, rapid and equitable evidence synthesis and guideline development: results from the COVID-19 evidence network to support decision-making (COVID-END).
151:88-95.
2022
-
A systematic review of meta-research studies finds substantial methodological heterogeneity in citation analyses to monitor evidence-based research.
150:126-141.
2022
-
Evidence to decision frameworks enabled structured and explicit development of healthcare recommendations.
150:51-62.
2022
-
GRADE Guidance 34: update on rating imprecision using a minimally contextualized approach.
150:216-224.
2022
-
GRADE guidance 35: update on rating imprecision for assessing contextualized certainty of evidence and making decisions.
150:225-242.
2022
-
Serious reporting deficiencies exist in minimal important difference studies: current state and suggestions for improvement.
150:25-32.
2022
-
A framework is proposed for defining, categorizing, and assessing conflicts of interest in health research.
149:236-243.
2022
-
A meta-research study of randomized controlled trials found infrequent and delayed availability of protocols.
149:45-52.
2022
-
A systematic survey of methods guidance suggests areas for improvement regarding access, development, and transparency.
149:217-226.
2022
-
Analytical frameworks in colorectal cancer guidelines: development of methods for systematic reviews, their application and practical guidance for their use.
149:206-216.
2022
-
Reporting of funding and conflicts of interest improved from preprints to peer-reviewed publications of biomedical research.
149:146-153.
2022
-
A multistakeholder development process to prioritize and translate COVID-19 health recommendations for patients, caregivers and the public. A case study of the COVID-19 recommendation map.
148:104-114.
2022
-
Causal language use in systematic reviews of observational studies is often inconsistent with intent: a systematic survey.
148:65-73.
2022
-
Indirectness (transferability) is critical when considering existing economic evaluations for GRADE clinical practice guidelines: a systematic review.
148:81-92.
2022
-
An evaluation of the COVID-19 recommendation map identified diverging clinical and public health guidance.
147:83-94.
2022
-
GRADE summary of findings tables enhanced understanding of values and preferences evidence.
147:60-68.
2022
-
Pooling of cohort studies and RCTs affects GRADE certainty of evidence in nutrition research.
147:151-159.
2022
-
The construct of certainty of evidence has not been disseminated to systematic reviews and clinical practice guidelines: author's reply.
147:173-173.
2022
-
The currency and completeness of specialized databases of COVID-19 publications.
147:52-59.
2022
-
Using Explicit Thresholds were valuable for judging Benefits and Harms in partially contextualized GRADE Guidelines.
147:69-75.
2022
-
Biological plausibility in environmental health systematic reviews: a GRADE concept paper.
146:32-46.
2022
-
Methodological approaches for developing, reporting, and assessing evidence-based clinical practice guidelines: a systematic survey.
146:77-85.
2022
-
Policies of biomedical preprint servers on conflicts of interest, authorship, and research integrity lacked important details.
146:47-59.
2022
-
Standardized wording to improve efficiency and clarity of GRADE EtD frameworks in health guidelines.
146:106-122.
2022
-
The use of the GRADE dose–response gradient domain in nutrition evidence syntheses varies considerably.
146:12-21.
2022
-
Minimal important changes in standard deviation units are highly variable and no universally applicable value can be determined.
145:92-100.
2022
-
A memorandum of understanding has facilitated guideline development involving collaborating groups.
144:8-15.
2022
-
GRADE concept paper 2: Concepts for judging certainty on the calibration of prognostic models in a body of validation studies.
143:202-211.
2022
-
New methods facilitated the process of prioritizing questions and health outcomes in guideline development.
143:91-104.
2022
-
Visual transformation for guidelines presentation of the strength of recommendations and the certainty of evidence.
143:178-185.
2022
-
A systematic survey identified methodological issues in studies estimating anchor-based minimal important differences in patient-reported outcomes.
142:144-151.
2022
-
Challenges of evidence synthesis during the 2020 COVID pandemic: a scoping review.
142:10-18.
2022
-
GRADE guidance 24 optimizing the integration of randomized and non-randomized studies of interventions in evidence syntheses and health guidelines.
142:200-208.
2022
-
Guidelines developed under pressure. The case of the COVID-19 low-quality “rapid” guidelines and potential solutions.
142:194-199.
2022
-
International alliance and AGREE-ment of 71 clinical practice guidelines on the management of critical care patients with COVID-19: a living systematic review.
142:333-370.
2022
-
Small differences in EQ-5D-5L health utility scores were interpreted differently between and within respondents.
142:133-143.
2022
-
The use of GRADE approach in Cochrane reviews of TCM was insufficient: a cross-sectional survey.
142:1-9.
2022
-
A few panel members dominated guideline development meeting discussions: Social network analysis.
141:1-10.
2022
-
A taxonomy and framework for identifying and developing actionable statements in guidelines suggests avoiding informal recommendations.
141:161-171.
2022
-
Focus groups and interviews with the public led to the development of a template for a GRADE Plain Language Recommendation (PLR).
141:18-25.
2022
-
More work needed on decision analysis for shared decision-making: A scoping review.
141:106-120.
2022
-
A modeling approach to derive baseline risk estimates for GRADE recommendations: Concepts, development, and results of its application to the American Society of Hematology 2019 guidelines on prevention of venous thromboembolism in surgical hospitalized patients.
140:69-78.
2021
-
Response to Weinfurt and Cappelleri on “Patient reported outcome measures in clinical trials should be initially analyzed as continuous outcomes for statistical significance and responder analyses should be reserved as secondary analyses”.
140:1-2.
2021
-
Update on the JCE GRADE series and other GRADE article types.
140:163-164.
2021
-
Clinical trials in COVID-19 management & prevention: A meta-epidemiological study examining methodological quality.
139:68-79.
2021
-
GRADE Notes 2: Criteria for searching non-randomized or indirect evidence should be defined early in the guideline production process.
139:210-213.
2021
-
GRADE guidelines 33: Addressing imprecision in a network meta-analysis.
139:49-56.
2021
-
Pearls on science, collaboration, and mentorship in health research: A masterclass conversation with Dr. John Ioannidis.
139:235-239.
2021
-
RIGHT for acupuncture: An extension of the RIGHT statement for clinical practice guidelines on acupuncture.
139:330-339.
2021
-
Reporting quality of trial protocols improved for non-regulated interventions but not regulated interventions: A repeated cross-sectional study.
139:340-349.
2021
-
Understanding treatment-subgroup effect in primary and secondary prevention of cardiovascular disease: An exploration using meta-analyses of individual patient data.
139:160-166.
2021
-
Clinical practice guidelines in low and middle income countries: experiences from colombia.
138:232-233.
2021
-
Development and application of health outcome descriptors facilitated decision-making in the production of practice guidelines.
138:115-127.
2021
-
Reconciling contrasting guideline recommendations on red and processed meat for health outcomes.
138:215-218.
2021
-
“Evidence-based checklists” for identifying predatory journals have not been assessed for reliability or validity: An analysis and proposal for moving forward.
138:40-48.
2021
-
Corrigendum to GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol 2011;64:1283–1293.
137:265-265.
2021
-
GRADE guidelines 32: GRADE offers guidance on choosing targets of GRADE certainty of evidence ratings.
137:163-175.
2021
-
GRADE notes: How to use GRADE when there is “no” evidence? A case study of the expert evidence approach.
137:231-235.
2021
-
Shifting the focus away from binary thinking of statistical significance and towards education for key stakeholders: revisiting the debate on whether it's time to de-emphasize or get rid of statistical significance.
137:104-112.
2021
-
Certainty of evidence and intervention's benefits and harms are key determinants of guidelines’ recommendations.
136:1-9.
2021
-
GRADE Guidance: 31. Assessing the certainty across a body of evidence for comparative test accuracy.
136:146-156.
2021
-
Guidelines that use the GRADE approach often fail to provide complete economic information for recommendations: A systematic survey.
136:203-215.
2021
-
Challenges in applying the GRADE approach in public health guidelines and systematic reviews: a concept article from the GRADE Public Health Group.
135:42-53.
2021
-
Getting trustworthy guidelines into the hands of decision-makers and supporting their consideration of contextual factors for implementation globally: recommendation mapping of COVID-19 guidelines.
135:182-186.
2021
-
Use of GRADE in evidence syntheses published in high-impact-factor nutrition journals: A methodological survey.
135:54-69.
2021
-
Patient reported outcome measures in clinical trials should be initially analyzed as continuous outcomes for statistical significance and responder analyses should be reserved as secondary analyses.
134:95-102.
2021
-
Recommendation mapping of the World Health Organization's guidelines on tuberculosis: A new approach to digitizing and presenting recommendations.
134:138-149.
2021
-
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.
134:178-189.
2021
-
Transparency, trust and minimizing burden to increase recruitment and retention in trials: a systematic review.
134:35-51.
2021
-
Will COVID-19 result in a giant step backwards for women in academic science?.
134:160-166.
2021
-
A conversation on health research collaborations and career with Dr. Gordon Guyatt: A commentary.
133:152-155.
2021
-
Minimal important difference estimates for patient-reported outcomes: A systematic survey.
133:61-71.
2021
-
A meta-research study revealed several challenges in obtaining placebos for investigator-initiated drug trials.
131:70-78.
2021
-
Evidence, values, and masks for control of COVID-19.
131:152-157.
2021
-
GRADE Concept Paper 1: Validating the “F.A.C.E” instrument using stakeholder perceptions of feasibility, acceptability, cost, and equity in guideline implement.
131:133-140.
2021
-
The movement for adopting or adapting clinical guidelines and recommendations.
131:166-167.
2021
-
Erratum to “What to do with all the AGREEs? The AGREE Portfolio of tools to support the guideline enterprise” [Journal of Clinical Epidemiology 125C (2020) 191-197].
130:174-174.
2021
-
Guidelines rarely used GRADE and applied methods inconsistently: A methodological study of Australian guidelines.
130:125-134.
2021
-
Supporting effective participation in health guideline development groups: The Guideline Participant Tool.
130:42-48.
2021
-
Using GRADE evidence to decision frameworks to choose from multiple interventions.
130:117-124.
2021
-
A framework for practical issues was developed to inform shared decision-making tools and clinical guidelines.
129:104-113.
2021
-
Developing trustworthy recommendations as part of an urgent response (1–2 weeks): a GRADE concept paper.
129:1-11.
2021
-
GRADE Guidelines 30: the GRADE approach to assessing the certainty of modeled evidence—An overview in the context of health decision-making.
129:138-150.
2021
-
GRADE Guidelines: 29. Rating the certainty in time-to-event outcomes—Study limitations due to censoring of participants with missing data in intervention studies.
129:126-137.
2021
-
Reply to letter to the editor “the NNTnet metric is not new, not easy to use, and not routinely applied in medical research”.
129:198-199.
2021
-
A framework for identifying and mitigating the equity harms of COVID-19 policy interventions.
128:35-48.
2020
-
A practical guide for using a survey about attitudes and behaviors to inform health care decisions.
128:93-100.
2020
-
Erratum to “Controversy and debate series on core outcome sets. Paper 3:debate on paper 1 from the perspective of GRADE [Grading of Recommendations Assessment, Development and Evaluation]” [Journal of Clinical Epidemiology 125C (2020) 216-221].
128:162-162.
2020
-
Prerandomization run-in periods in randomized controlled trials of chronic diseases: a methodological study.
128:148-156.
2020
-
Response to “Trials for depressive disorder in adolescents: the emperor's new clothes,” a letter to the editor by Alain Braillon, MD, PhD.
128:159-161.
2020
-
Assessing concordance of financial conflicts of interest disclosures with payments’ databases: a systematic survey of the health literature.
127:19-28.
2020
-
Authors of clinical trials seldom reported details when declaring their individual and institutional financial conflicts of interest: a cross-sectional survey.
127:49-58.
2020
-
Commentary: Quest for using sound evidence when making decisions about screening.
127:220-222.
2020
-
Delphi consensus on core criteria set selecting among health-related outcome measures (HROM) in primary health care.
127:105-116.
2020
-
Over half of the WHO guidelines published from 2014 to 2019 explicitly considered health equity issues: a cross-sectional survey.
127:125-133.
2020
-
Publisher's note regarding “the short-form chronic respiratory disease questionnaire was a valid, reliable, and responsive quality-of-life instrument in acute exacerbations of chronic obstructive pulmonary disease” [J Clin Epidemiol. 2008;61:489-497].
127:250-250.
2020
-
Quality assessment of prevalence studies: a systematic review.
127:59-68.
2020
-
Social media can have an impact on how we manage and investigate the COVID-19 pandemic.
127:198-201.
2020
-
Using GRADE in situations of emergencies and urgencies: certainty in evidence and recommendations matters during the COVID-19 pandemic, now more than ever and no matter what.
127:202-207.
2020
-
Evidence-based medicine in times of crisis.
126:164-166.
2020
-
External validation demonstrated the Ottawa SAH prediction models can identify pSAH using health administrative data.
126:122-130.
2020
-
How personalized are benefit and harm results of randomized trials? A systematic review.
126:17-25.
2020
-
Open synthesis and the coronavirus pandemic in 2020.
126:184-191.
2020
-
Rapid review methods more challenging during COVID-19: commentary with a focus on 8 knowledge synthesis steps.
126:177-183.
2020
-
Systematic scoping review identifies heterogeneity in outcomes measured in adolescent depression clinical trials.
126:71-79.
2020
-
The UpPriority tool was developed to guide the prioritization of clinical guideline questions for updating.
126:80-92.
2020
-
A large number of COVID-19 interventional clinical trials were registered soon after the pandemic onset: a descriptive analysis.
125:170-178.
2020
-
An overview of platform trials with a checklist for clinical readers.
125:1-8.
2020
-
Controversy and Debate Series on Core Outcome Sets: The SOLAR (Standardized Outcomes Linking Across StakeholdeRs) system and hub and spokes model for direct core outcome measures in health care and its relation to GRADE.
125:216-221.
2020
-
The number needed to treat for net effect (NNTnet) as a metric for measuring combined benefits and harms.
125:100-107.
2020
-
What to do with all the AGREEs? The AGREE portfolio of tools to support the guideline enterprise.
125:191-197.
2020
-
Guideline developers in the United States were inconsistent in applying criteria for appropriate Grading of Recommendations, Assessment, Development and Evaluation use.
124:193-199.
2020
-
Measuring multimorbidity series. An overlooked complexity - Comparison of self-report vs. administrative data in community-living adults: Paper 3. Agreement across data sources and implications for estimating associations with health service use.
124:173-182.
2020
-
Measuring multimorbidity series: an overlooked complexity—comparison of self-report vs. administrative data in community-living adults—paper 1: introduction.
124:160-162.
2020
-
Measuring multimorbidity series—an overlooked complexity comparison of self-report vs. administrative data in community-living adults: paper 2. Prevalence estimates depend on the data source.
124:163-172.
2020
-
The fragility of trial results involves more than statistical significance alone.
124:34-41.
2020
-
A systematic survey showed important limitations in the methods for assessing drug safety among systematic reviews.
123:80-90.
2020
-
COVID-19 coronavirus research has overall low methodological quality thus far: case in point for chloroquine/hydroxychloroquine.
123:120-126.
2020
-
Erratum to “A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analyses” [J Clin Epidemiol. 2019;113:159-67].
123:189-189.
2020
-
Exclusion of studies with no events in both arms in meta-analysis impacted the conclusions.
123:91-99.
2020
-
Future of Evidence Ecosystem Series: Evidence synthesis 2.0: when systematic, scoping, rapid, living, and overviews of reviews come together.
123:162-165.
2020
-
Conclusions from surveys may not consider important biases: a systematic survey of surveys.
122:108-114.
2020
-
GRADE guidelines: 21 part 1. Study design, risk of bias, and indirectness in rating the certainty across a body of evidence for test accuracy.
122:129-141.
2020
-
GRADE guidelines: 21 part 2. Test accuracy: inconsistency, imprecision, publication bias, and other domains for rating the certainty of evidence and presenting it in evidence profiles and summary of findings tables.
122:142-152.
2020
-
A call for consensus guidelines on classification and reporting of methodological studies.
121:110-112.
2020
-
GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks.
121:62-70.
2020
-
Optimal sampling in derivation studies was associated with improved discrimination in external validation for heart failure prognostic models.
121:71-80.
2020
-
Reply to letter to the editor “Forrest plots or caterpillar plots?”.
121:110-110.
2020
-
A common framework of steps and criteria for prioritizing topics for evidence syntheses: a systematic review.
120:67-85.
2020
-
A systematic review evaluating screening instruments for gambling disorder finds lack of adequate evidence.
120:86-93.
2020
-
Grading of Recommendations Assessment, Development, and Evaluations (GRADE) notes: extremely serious, GRADE's terminology for rating down by three levels.
120:116-120.
2020
-
GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions.
119:126-135.
2020
-
GRADE guidelines 27: how to calculate absolute effects for time-to-event outcomes in summary of findings tables and Evidence Profiles.
118:124-131.
2020
-
A scoping review shows that several nonvalidated budget planning tools for randomized trials are available.
117:9-19.
2020
-
Calculation of absolute risk for important outcomes in patients with and without a prognostic factor of interest.
117:46-51.
2020
-
Defining ranges for certainty ratings of diagnostic accuracy: a GRADE concept paper.
117:138-148.
2020
-
Multiple uses of forest plots in presenting analysis results in health research: A Tutorial.
117:89-98.
2020
-
Colorectal cancer guidelines seldom include the patient perspective.
116:84-97.
2019
-
Most guideline organizations lack explicit guidance in how to incorporate cost considerations.
116:72-83.
2019
-
Poor quality patient reported outcome measures bias effect estimates in orthopaedic randomized studies.
116:36-38.
2019
-
A guidance was developed to identify participants with missing outcome data in randomized controlled trials.
115:55-63.
2019
-
Development of the summary of findings table for network meta-analysis.
115:1-13.
2019
-
Statistical significance did not affect time to publication in non-Cochrane systematic reviews: a metaepidemiological study.
115:25-34.
2019
-
Collection of antirheumatic medication data from both patients and rheumatologists shows strong agreement in a real-world clinical cohort: the Ontario Best Practices Research Initiative—a rheumatoid arthritis cohort.
114:95-103.
2019
-
Single pivotal trials with few corroborating characteristics were used for FDA approval of cancer therapies.
114:49-59.
2019
-
A systematic survey identified 36 criteria for assessing effect modification claims in randomized trials or meta-analyses.
113:159-167.
2019
-
Engaging knowledge users in a systematic review on the comparative effectiveness of geriatrician-led models of care is possible: A cross-sectional survey using the Patient Engagement Evaluation Tool.
113:58-63.
2019
-
Several reasons explained the variation in the results of 22 meta-analyses addressing the same question.
113:147-158.
2019
-
Structured decision-making drives guidelines panels' recommendations “for” but not “against” health interventions.
110:23-33.
2019
-
The selection of comparators for randomized controlled trials of health-related behavioral interventions: recommendations of an NIH expert panel.
110:74-81.
2019
-
A modified Delphi and cross-sectional survey to facilitate selection of optimal outcomes and measures for a systematic review on geriatrician-led care models.
109:117-124.
2019
-
An evidence rating service provided valid correlates of the clinical importance of medical articles and journals.
109:80-89.
2019
-
Conflict of interest is not associated with positive conclusions in toothpaste trials: a systematic survey.
108:141-143.
2019
-
Corrigendum to “Studies reporting ROC curves of diagnostic and prediction data were incorporated into meta-analyses using corresponding odds ratios” [J Clin Epidemiol. 2007 May;60(5):530-4].
108:147-147.
2019
-
GRADE approach to rate the certainty from a network meta-analysis: addressing incoherence.
108:77-85.
2019
-
Getting more out of meta-analyses: a new approach to meta-analysis in light of unexplained heterogeneity.
107:101-106.
2019
-
The methodological quality of dose-response meta-analyses needed substantial improvement: a cross-sectional survey and proposed recommendations.
107:1-11.
2019
-
GRADE Guidelines: 22. The GRADE approach for tests and strategies-from test accuracy to patient important outcomes and recommendations.
111:69-82.
2019
-
GRADE approach to rate the certainty from a network meta-analysis: avoiding spurious judgments of imprecision in sparse networks.
105:60-67.
2019
-
Multimorbidity and comorbidity revisited: refining the concepts for international health research.
105:142-146.
2019
-
Potentially missing data are considerably more frequent than definitely missing data: a methodological survey of 638 randomized controlled trials.
106:18-31.
2019
-
The reporting of safety among drug systematic reviews was poor before the implementation of the PRISMA harms checklist.
105:125-135.
2019
-
Certainty ranges facilitated explicit and transparent judgments regarding evidence credibility.
104:46-51.
2018
-
Evidence to Decision framework provides a structured “roadmap” for making GRADE guidelines recommendations.
104:103-112.
2018
-
Subgroup analyses are seldom possible and subgroup effects are rare in Cochrane HIV systematic reviews.
104:143-144.
2018
-
GRADEing the un-GRADE-able: a description of challenges in applying GRADE methods to the ethical and implementation questions of pediatric organ donation guidelines.
103:134-137.
2018
-
Guidance was developed on how to write a plain language summary for diagnostic test accuracy reviews.
103:112-119.
2018
-
Applying GRADE to a network meta-analysis of antidepressants led to more conservative conclusions.
102:87-98.
2018
-
GRADE weak or conditional recommendations mandate shared decision-making. Author Response.
102:147-148.
2018
-
Statistician credit for collaboration requires extending the number of cited authors in research publications.
101:130-131.
2018
-
A scoping review and survey provides the rationale, perceptions, and preferences for the integration of randomized and nonrandomized studies in evidence syntheses and GRADE assessments.
98:33-40.
2018
-
Corrigendum to “Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis” [J Clin Epidemiol 2018;93:36-44].
98:162-162.
2018
-
Using decision thresholds for ranking treatments in network meta-analysis results in more informative rankings.
98:62-69.
2018
-
Explaining odds ratios as conditional risk ratios.
97:123-124.
2018
-
Multiple overlapping systematic reviews facilitate the origin of disputes: the case of thrombolytic therapy for pulmonary embolism.
97:1-13.
2018
-
Retrospective assessment of resource use and costs in two investigator-initiated randomized trials exemplified a comprehensive cost item list.
96:73-83.
2018
-
Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data.
96:1-11.
2018
-
Controversy and debate on dengue vaccine series—paper 1: review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs.
95:137-139.
2018
-
Controversy and debate on dengue vaccine series—paper 3: final response to review of a licensed dengue vaccine: inappropriate subgroup analyses and selective reporting may cause harm in mass vaccination programs.
95:142-142.
2018
-
Guideline on terminology and definitions of updating clinical guidelines: The Updating Glossary.
95:28-33.
2018
-
The efficiency of database searches for creating systematic reviews was improved by search filters.
95:1-6.
2018
-
Decision-making frameworks and considerations for informing coverage decisions for healthcare interventions: a critical interpretive synthesis.
94:143-150.
2018
-
Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis.
93:36-44.
2018
-
Do clinicians want recommendations? A multicenter study comparing evidence summaries with and without GRADE recommendations.
99:33-40.
2018
-
GRADE Guidelines: 19. Assessing the certainty of evidence in the importance of outcomes or values and preferences—Risk of bias and indirectness.
111:94-104.
2018
-
GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence.
111:105-114.
2018
-
GRADE guidelines: 20. Assessing the certainty of evidence in the importance of outcomes or values and preferences—inconsistency, imprecision, and other domains.
111:83-93.
2018
-
Potentially missing data was considerably more frequent than definitely missing data in randomized controlled trials: A methodological survey
2018
-
Systematic reviews do not adequately report or address missing outcome data in their analyses: a methodological survey.
99:14-23.
2018
-
Decision making about healthcare-related tests and diagnostic test strategies. Paper 1: a new series on testing to improve people's health.
92:16-17.
2017
-
Decision making about healthcare-related tests and diagnostic test strategies. Paper 2: a review of methodological and practical challenges.
92:18-28.
2017
-
Decision making about healthcare-related tests and diagnostic test strategies. Paper 3: a systematic review shows limitations in most tools designed to assess quality and develop recommendations.
92:29-37.
2017
-
Decision making about healthcare-related tests and diagnostic test strategies. Paper 4: International guidelines show variability in their approaches.
92:38-46.
2017
-
Decision making about healthcare-related tests and diagnostic test strategies. Paper 5: a qualitative study with experts suggests that test accuracy data alone is rarely sufficient for decision making.
92:47-57.
2017
-
Congruence between patient characteristics and interventions may partly explain medication adherence intervention effectiveness: an analysis of 190 randomized controlled trials from a Cochrane systematic review.
91:70-79.
2017
-
Montreal Accord on Patient-Reported Outcomes (PROs) use series–Paper 7: modern perspectives of measurement validation emphasize justification of inferences based on patient reported outcome scores.
89:154-159.
2017
-
Quasi-experimental study designs series—paper 11: supporting the production and use of health systems research syntheses that draw on quasi-experimental study designs.
89:92-97.
2017
-
Quasi-experimental study designs series—paper 4: uses and value.
89:21-29.
2017
-
Deficiencies in addressing effect modification in network meta-analyses: a meta-epidemiological survey.
88:47-56.
2017
-
Incorporating patients' views in guideline development: a systematic review of guidance documents.
88:102-112.
2017
-
Testing the effectiveness of simplified search strategies for updating systematic reviews.
88:148-153.
2017
-
Magnitude and direction of missing confounders had different consequences on treatment effect estimation in propensity score analysis.
87:87-97.
2017
-
Applying GRADE to Coverage Decisions: Results of a Stakeholder Survey and Workshop.
86:129-139.
2017
-
Forty-two systematic reviews generated 23 items for assessing the risk of bias in values and preferences' studies.
85:21-31.
2017
-
A systematic review found that deviations from intention-to-treat are common in randomized trials and systematic reviews.
84:37-46.
2017
-
EBM has not only called out the problems but offered solutions.
84:8-10.
2017
-
Response to letter to the editor by A. Huitfeldt Re: Odds ratios deconstructed: a new way to understand and explain odds ratios as conditional risk ratios.
84:191-192.
2017
-
Simple randomization did not protect against bias in smaller trials.
84:105-113.
2017
-
Criteria for use of composite end points for competing risks—a systematic survey of the literature with recommendations.
82:4-11.
2017
-
Odds ratios deconstructed: A new way to understand and explain odds ratios as conditional risk ratios.
82:87-93.
2017
-
A methodological survey identified eight proposed frameworks for the adaptation of health related guidelines.
86:3-10.
2017
-
A systematic survey of the methods literature on the reporting quality and optimal methods of handling participants with missing outcome data for continuous outcomes in randomized controlled trials.
88:67-80.
2017
-
A systematic survey on reporting and methods for handling missing participant data for continuous outcomes in randomized controlled trials.
88:57-66.
2017
-
Authors of clinical trials reported individual and financial conflicts of interest more frequently than institutional and nonfinancial ones: a methodological survey.
87:78-86.
2017
-
Authors seldom report the most patient-important outcomes and absolute effect measures in systematic review abstracts.
81:3-12.
2017
-
Equity issues were not fully addressed in Cochrane human immunodeficiency virus systematic reviews.
81:96-100.
2017
-
GRADE Equity Guidelines 2: Considering health equity in GRADE guideline development: Equity extension of the Guideline Development Checklist.
90:68-75.
2017
-
GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT.
81:101-110.
2017
-
GRADE equity guidelines 1: considering health equity in GRADE guideline development: introduction and rationale.
90:59-67.
2017
-
GRADE equity guidelines 3: considering health equity in GRADE guideline development: rating the certainty of synthesized evidence.
90:76-83.
2017
-
GRADE equity guidelines 4: Guidance on how to assess and address health equity within the evidence to decision process
2017
-
GRADE equity guidelines 4: considering health equity in GRADE guideline development: evidence to decision process.
90:84-91.
2017
-
GRADE guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence.
87:14-22.
2017
-
Guideline conflict of interest management and methodology heavily impacts on the strength of recommendations: comparison between two iterations of the American College of Chest Physicians Antithrombotic Guidelines.
81:141-143.
2017
-
Guideline conflict of interest management and methodology heavily impacts on the strength of recommendations: comparison between two iterations of the American College of Chest Physicians Antithrombotic Guidelines..
81:141-143.
2017
-
Improvement evident but still necessary in clinical practice guideline quality: a systematic review.
81:13-21.
2017
-
Living systematic review: 1. Introduction—the why, what, when, and how.
91:23-30.
2017
-
Living systematic reviews: 2. Combining human and machine effort.
91:31-37.
2017
-
Living systematic reviews: 3. Statistical methods for updating meta-analyses.
91:38-46.
2017
-
Living systematic reviews: 4. Living guideline recommendations.
91:47-53.
2017
-
Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications.
81:56-63.
2017
-
RE: Which estimates comprise optimal reporting in systematic reviews?.
81:140-141.
2017
-
Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit.
82:12-19.
2017
-
Systematic survey of randomized trials evaluating the impact of alternative diagnostic strategies on patient-important outcomes.
84:61-69.
2017
-
The GRADE Working Group clarifies the construct of certainty of evidence.
87:4-13.
2017
-
Which estimates comprise optimal reporting in Systematic Reviews?.
81:140-141.
2017
-
A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable.
80:8-15.
2016
-
Meta-analysis on continuous outcomes in minimal important difference units: an application with appropriate variance calculations.
80:57-67.
2016
-
Methods for detecting, quantifying, and adjusting for dissemination bias in meta-analysis are described.
80:25-33.
2016
-
Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research?.
80:16-24.
2016
-
Limited responsiveness related to the minimal important difference of patient-reported outcomes in rare diseases.
79:10-21.
2016
-
Randomized trials are frequently fragmented in multiple secondary publications.
79:130-139.
2016
-
The reporting of studies using routinely collected health data was often insufficient.
79:104-111.
2016
-
CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement.
76:9-17.
2016
-
N of 1 randomized trials: a commentary.
76:4-5.
2016
-
Automatically quantifying the scientific quality and sensationalism of news records mentioning pandemics: validating a maximum entropy machine-learning model.
75:47-55.
2016
-
Diverse criteria and methods are used to compare treatment effect estimates: a scoping review.
75:29-39.
2016
-
GRADE guidelines system is reproducible when instructions are clearly operationalized even among the guidelines panel members with limited experience with GRADE.
75:115-118.
2016
-
Interpreting GRADE's levels of certainty or quality of the evidence: GRADE for statisticians, considering review information size or less emphasis on imprecision?.
75:6-15.
2016
-
A Rasch analysis of the Brief Pain Inventory Interference subscale reveals three dimensions and an age bias.
74:218-226.
2016
-
Critical EPICOT items were absent in Cochrane human immunodeficiency virus systematic reviews: a bibliometric analysis.
74:66-72.
2016
-
Improving GRADE evidence tables part 2: a systematic survey of explanatory notes shows more guidance is needed.
74:19-27.
2016
-
Rating the quality of evidence is by necessity a matter of judgment.
74:237-238.
2016
-
Dave Sackett and the ethos of the EBM community.
73:75-81.
2016
-
David Sackett's legacy includes evidence-based mentorship.
73:61-63.
2016
-
Modified intention-to-treat analysis did not bias trial results.
72:66-74.
2016
-
World Health Organization strong recommendations based on low-quality evidence (study quality) are frequent and often inconsistent with GRADE guidance.
72:98-106.
2016
-
A number of factors explain why WHO guideline developers make strong recommendations inconsistent with GRADE guidance.
70:111-122.
2016
-
An international survey and modified Delphi approach revealed numerous rapid review methods.
70:61-67.
2016
-
High statistical heterogeneity is more frequent in meta-analysis of continuous than binary outcomes.
70:129-135.
2016
-
Senior GRADE methodologists encounter challenges as part of WHO guideline development panels: an inductive content analysis.
70:123-128.
2016
-
A guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach.
72:45-55.
2016
-
A very low number of national adaptations of the World Health Organization guidelines for HIV and tuberculosis reported their processes.
80:50-56.
2016
-
An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
69:152-160.
2016
-
GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health.
76:89-98.
2016
-
Guideline panels should seldom make good practice statements: guidance from the GRADE Working Group.
80:3-7.
2016
-
Improving GRADE evidence tables part 1: a randomized trial shows improved understanding of content in summary of findings tables with a new format.
74:7-18.
2016
-
Improving GRADE evidence tables part 3: detailed guidance for explanatory footnotes supports creating and understanding GRADE certainty in the evidence judgments.
74:28-39.
2016
-
Sensitivity subgroup analysis based on single-center vs. multi-center trial status when interpreting meta-analyses pooled estimates: the logical way forward.
74:80-92.
2016
-
Systematic reviews experience major limitations in reporting absolute effects.
72:16-26.
2016
-
The skills and experience of GRADE methodologists can be assessed with a simple tool.
79:150-158.
2016
-
Three challenges described for identifying participants with missing data in trials reports, and potential solutions suggested to systematic reviewers.
76:147-154.
2016
-
The choice of the noninferiority margin in clinical trials was driven by baseline risk, type of primary outcome, and benefits of new treatment.
68:1144-1151.
2015
-
Although not consistently superior, the absolute approach to framing the minimally important difference has advantages over the relative approach.
68:888-894.
2015
-
Quality of evidence is a key determinant for making a strong GRADE guidelines recommendation.
68:727-732.
2015
-
Copresentation of relative and absolute effects is essential to promote optimal interpretability of treatment effects.
68:355-356.
2015
-
A summary to communicate evidence from systematic reviews to the public improved understanding and accessibility of information: a randomized controlled trial.
68:182-190.
2015
-
Statistical approaches to harmonize data on cognitive measures in systematic reviews are rarely reported.
68:154-162.
2015
-
Erratum to" GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles–continuous outcomes"[J Clin Epidemiol 2013; 66 (2): 173-183].
68:475-475.
2015
-
Guideline panels should not GRADE good practice statements.
68:597-600.
2015
-
Adherence measurement and patient recruitment methods are poor in intervention trials to improve patient adherence.
67:1076-1082.
2014
-
Erratum to “Using GRADE for evaluating the quality of evidence in hyperbaric oxygen therapy clarifies evidence limitations” [J Clin Epidemiol 2014;67(1):65-72].
67:1178-1178.
2014
-
Perceptions of authors' contributions are influenced by both byline order and designation of corresponding author.
67:1049-1054.
2014
-
Validation of international algorithms to identify adults with inflammatory bowel disease in health administrative data from Ontario, Canada.
67:887-896.
2014
-
Applying Grading of Recommendations Assessment, Development and Evaluation (GRADE) to diagnostic tests was challenging but doable.
67:760-768.
2014
-
Blinded interpretation of study results can feasibly and effectively diminish interpretation bias.
67:769-772.
2014
-
The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index.
67:622-628.
2014
-
World Health Organization recommendations are often strong based on low confidence in effect estimates.
67:629-634.
2014
-
An efficient strategy allowed English-speaking reviewers to identify foreign-language articles eligible for a systematic review.
67:547-553.
2014
-
An efficient strategy allowed English-speaking reviewers to identify foreign-language articles eligible for a systematic review.
67:547-553.
2014
-
A charitable donation incentive did not increase physician survey response rates in a randomized trial.
67:482-483.
2014
-
A users' guide to understanding therapeutic substitutions.
67:305-313.
2014
-
Letter reply to GRADE guidelines articles 14 and 15.
67:240-240.
2014
-
Addressing continuous data measured with different instruments for participants excluded from trial analysis: a guide for systematic reviewers.
67:560-570.
2014
-
Considering intellectual, in addition to financial, conflicts of interest proved important in a clinical practice guideline: a descriptive study.
67:1222-1228.
2014
-
Perceived disagreement (mostly) not confirmed by evidence … A reply to Watine et al.: Clinical practice guidelines: myths and misconceptions.
67:10-14.
2014
-
The Quick Mild Cognitive Impairment screen correlated with the Standardized Alzheimer's Disease Assessment Scale–cognitive section in clinical trials.
67:87-92.
2014
-
Using GRADE for evaluating the quality of evidence in hyperbaric oxygen therapy clarifies evidence limitations.
67:65-72.
2014
-
A survey of patient's perceptions of what is “adverse” in manual physiotherapy and predicting who is likely to say so.
66:1184-1191.
2013
-
Testing the Risk of Bias tool showed low reliability between individual reviewers and across consensus assessments of reviewer pairs.
66:973-981.
2013
-
Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study.
66:847-855.
2013
-
Clinical experience may affect clinician compliance with assigned treatment in randomized trials.
66:768-774.
2013
-
GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength.
66:726-735.
2013
-
Health-related quality-of-life data should be regarded as a vital sign.
66:706-709.
2013
-
Essential Evidence Plus correctly evaluated by survey: midranked of 10 evidence-informed medical resources.
66:696-697.
2013
-
Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences.
66:415-425.
2013
-
Citation bias favoring statistically significant studies was present in medical research.
66:296-301.
2013
-
GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence.
66:140-150.
2013
-
GRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomes.
66:158-172.
2013
-
GRADE guidelines—an introduction to the 10th–13th articles in the series.
66:121-123.
2013
-
Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers.
66:1014-1021.
2013
-
GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes.
66:151-157.
2013
-
GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles—continuous outcomes.
66:173-183.
2013
-
GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations.
66:719-725.
2013
-
Randomized trials published in higher vs. lower impact journals differ in design, conduct, and analysis.
66:286-295.
2013
-
The GRADE approach is reproducible in assessing the quality of evidence of quantitative evidence syntheses.
66:736-742.
2013
-
Calculating additive treatment effects from multiple randomized trials provides useful estimates of combination therapies.
65:1282-1288.
2012
-
Experience with GRADE.
65:1243-1244.
2012
-
The quality, breadth, and timeliness of content updating vary substantially for 10 online medical texts: an analytic survey.
65:1289-1295.
2012
-
Rasch analysis of the PedsQL: an increased understanding of the properties of a rating scale.
65:1117-1123.
2012
-
A survey of physicians show a one-third reduction in harmful outcomes to be a clinically important difference for statin therapy.
65:954-961.
2012
-
Application of the systematic review and bibliometric network analysis (SeBriNA) methodology contextualizes evidence. Part 2: rituximab for non-Hodgkin's lymphoma.
65:996-1009.
2012
-
The systematic review and bibliometric network analysis (SeBriNA) is a new method to contextualize evidence. Part 1: description.
65:1010-1015.
2012
-
Treatment effects on patient-important outcomes can be small, even with large effects on surrogate markers.
65:940-945.
2012
-
New methods can extend the use of minimal important difference units in meta-analyses of continuous outcome measures.
65:817-826.
2012
-
Value of information methods for planning and analyzing clinical studies optimize decision making and research planning.
65:870-876.
2012
-
Author’s specialty and conflicts of interest contribute to conflicting guidelines for screening mammography.
65:725-733.
2012
-
Hearing, mobility, and pain predict mortality: a longitudinal population-based study.
65:764-777.
2012
-
Clinical practice guidelines and patient decision aids. An inevitable relationship.
65:584-589.
2012
-
Search filters can find some but not all knowledge translation articles in MEDLINE: an analytic survey.
65:651-659.
2012
-
The Global Rating Scale complements the AGREE II in advancing the quality of practice guidelines.
65:526-534.
2012
-
Studies of stroke rehabilitation therapies should report blinding and rationalize use of outcome measurement instruments.
65:368-374.
2012
-
Systematic reviews identify important methodological flaws in stroke rehabilitation therapy primary studies: review of reviews.
65:358-367.
2012
-
Erratum to: “CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials” [J Clin Epidemiol 2010;63(8):e1–37].
65:351-351.
2012
-
Formatting modifications in GRADE evidence profiles improved guideline panelists comprehension and accessibility to information. A randomized trial.
65:748-755.
2012
-
Inclusion of methodological filters in searches for diagnostic test accuracy studies misses relevant studies.
65:116-117.
2012
-
Making the best judgment of risk of bias.
65:1238-1238.
2012
-
McMaster Premium LiteratUre Service (PLUS) performed well for identifying new studies for updated Cochrane reviews.
65:62-72.e1.
2012
-
Methodologists and context experts disagreed regarding managing conflicts of interest of clinical practice guidelines panels.
65:734-739.
2012
-
Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid.
65:262-267.
2012
-
“Might” or “suggest”? No wording approach was clearly superior in conveying the strength of recommendation.
65:268-275.
2012
-
GRADE guidelines 6. Rating the quality of evidence—imprecision.
64:1283-1293.
2011
-
Performance of logistic regression modeling: beyond the number of events per variable, the role of data structure.
64:1463-1464.
2011
-
Sensitive Clinical Queries retrieved relevant systematic reviews as well as primary studies: an analytic survey.
64:1341-1349.
2011
-
Conducting quantitative synthesis when comparing medical interventions: AHRQ and the Effective Health Care Program.
64:1187-1197.
2011
-
Outcomes assessment in the SPRINT multicenter tibial fracture trial: Adjudication committee size has trivial effect on trial results.
64:1023-1033.
2011
-
Performance of logistic regression modeling: beyond the number of events per variable, the role of data structure.
64:993-1000.
2011
-
Selecting participants that raise a clinical trial’s population attributable fraction can increase the treatment effect within the trial and reduce the required sample size.
64:893-902.
2011
-
Testing a tool for the classification of study designs in systematic reviews of interventions and exposures showed moderate reliability and low accuracy.
64:861-871.
2011
-
Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences.
64:743-748.
2011
-
Randomized controlled trials of herbal interventions underreport important details of the intervention.
64:760-769.
2011
-
The difference between reliability and agreement.
64:701-702.
2011
-
Five preference-based indexes in cataract and heart failure patients were not equally responsive to change.
64:497-506.
2011
-
Prospectively screening for eligible patients was inaccurate in predicting patient recruitment of orthopedic randomized trials.
64:537-542.
2011
-
Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods.
64:556-564.
2011
-
GRADE guidelines: 2. Framing the question and deciding on important outcomes.
64:395-400.
2011
-
GRADE guidelines: 3. Rating the quality of evidence.
64:401-406.
2011
-
GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology.
64:380-382.
2011
-
Level of evidence and conflict of interest disclosure associated with higher citation rates in orthopedics.
64:331-338.
2011
-
Six-week response rates to an orthopedic surgeons' survey were not affected by academic incentives or administration modality.
64:339-340.
2011
-
Survival distributions impact the power of randomized placebo-phase design and parallel groups randomized clinical trials.
64:286-292.
2011
-
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables.
64:383-394.
2011
-
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias).
64:407-415.
2011
-
GRADE guidelines: 5. Rating the quality of evidence—publication bias.
64:1277-1282.
2011
-
GRADE guidelines: 7. Rating the quality of evidence—inconsistency.
64:1294-1302.
2011
-
GRADE guidelines: 8. Rating the quality of evidence—indirectness.
64:1303-1310.
2011
-
GRADE guidelines: 9. Rating up the quality of evidence.
64:1311-1316.
2011
-
Guidelines for Reporting Reliability and Agreement Studies (GRRAS) were proposed.
64:96-106.
2011
-
Study design attributes influenced patients' willingness to participate in clinical research: a randomized vignette-based study.
64:107-115.
2011
-
AGREE II: Advancing guideline development, reporting and evaluation in health care.
63:1308-1311.
2010
-
Response times follow lognormal or gamma distribution in arthritis patients.
63:1363-1369.
2010
-
A prospective global measure, the Punum Ladder, provides more valid assessments of quality of life than a retrospective transition measure.
63:1123-1131.
2010
-
Relative risk and odds ratio data are still portrayed with inappropriate scales in the medical literature.
63:1045-1047.
2010
-
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials.
63:e1-e37.
2010
-
CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials.
63:834-840.
2010
-
Community controls were preferred to hospital controls in a case–control study where the cases are derived from the hospital.
63:926-931.
2010
-
There was evidence of convergent and construct validity of Physiotherapy Evidence Database quality scale for physiotherapy trials.
63:920-925.
2010
-
Patient preferences before and after total knee arthroplasty.
63:774-782.
2010
-
Reflections on the minimal important difference: research is the ultimate goal, not the anchor.
63:806-806.
2010
-
The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes.
63:737-745.
2010
-
AHRQ Series Commentary 1: Rating the evidence in comparative effectiveness reviews.
63:474-475.
2010
-
AHRQ Series Paper 4: Assessing harms when comparing medical interventions: AHRQ and the Effective Health-Care Program.
63:502-512.
2010
-
BLISS index using WOMAC index detects between-group differences at low-intensity symptom states in osteoarthritis.
63:566-574.
2010
-
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials.
340:c869-c869.
2010
-
Trial sample size, but not trial quality, is associated with positive study outcome.
63:154-162.
2010
-
Local estimates of population attributable risk.
63:85-93.
2010
-
The minimal detectable change cannot reliably replace the minimal important difference.
63:28-36.
2010
-
Use of both short musculoskeletal function assessment questionnaire and short form-36 among tibial-fracture patients was redundant.
62:1210-1217.
2009
-
Indirect comparison: relative risk fallacies and odds solution.
62:1031-1036.
2009
-
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement.
62:1006-1012.
2009
-
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
62:e1-e34.
2009
-
Diagnostic test systematic reviews: Bibliographic search filters (“Clinical Queries”) for diagnostic accuracy studies perform well.
62:974-981.
2009
-
Estimating risk difference from relative association measures in meta-analysis can infrequently pose interpretational challenges.
62:865-867.
2009
-
Uncertainty in the minimum event risk to justify treatment was evaluated.
62:816-824.
2009
-
Conference abstracts of a new oncology drug do not always lead to full publication: Proceed with caution.
62:752-758.
2009
-
A new 'Mechanistic-Practical” Framework for designing and interpreting randomized trials.
62:479-484.
2009
-
Choice of data extraction tools for systematic reviews depends on resources and review complexity.
62:506-510.
2009
-
The practicalists' response.
62:489-494.
2009
-
The quality of reporting of trial abstracts is suboptimal: Survey of major general medical journals.
62:387-392.
2009
-
Using the entire cohort in the receiver operating characteristic analysis maximizes precision of the minimal important difference.
62:374-379.
2009
-
New study design evaluated the validity of measures to assess change after hip or knee arthroplasty.
62:347-352.
2009
-
The Internet is valid and reliable for child-report: An example using the Activities Scale for Kids (ASK) and the Pediatric Quality of Life Inventory (PedsQL).
62:314-320.
2009
-
Radiographs of hip fractures were digitally altered to mask surgeons to the type of implant without compromising the reliability of quality ratings or making the rating process more difficult.
62:214-223.e1.
2009
-
Systematic reviewers commonly contact study authors but do so with limited rigor.
62:138-142.
2009
-
The capture–mark–recapture technique can be used as a stopping rule when searching in systematic reviews.
62:149-157.
2009
-
Specific HRQL instruments and symptom scores were more responsive than preference-based generic instruments in patients with GERD.
62:102-110.
2009
-
The Completeness of Reporting (CORE) index identifies important deficiencies in observational study conference abstracts.
61:1241-1249.e2.
2008
-
Computerized adaptive test for patients with knee impairments produced valid and responsive measures of function.
61:1113-1124.
2008
-
Attention should be given to multiplicity issues in systematic reviews.
61:857-865.
2008
-
Commentary on “Alternative graphs for diagnostic tests: the agreement chart and the receiver operating characteristic curve”.
61:855-856.
2008
-
The agreement chart as an alternative to the receiver-operating characteristic curve for diagnostic tests.
61:866-874.
2008
-
Erratum to: “Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis”.
61:854-854.
2008
-
The reporting quality of meta-analyses improves: a random sampling study.
61:770-775.
2008
-
Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses.
61:763-769.
2008
-
Health Utilities Index Mark 3 showed valid in Alzheimer Disease, arthritis, and cataracts.
61:733-739.
2008
-
Qualiveen, a urinary-disorder specific instrument: 0.5 corresponds to the minimal important difference.
61:505-510.
2008
-
Systematic reviews and original articles differ in relevance, novelty, and use in an evidence-based service for physicians: PLUS project.
61:449-454.
2008
-
We must carefully choose how to spend limited time and energy to maximize positive impact.
61:413-413.
2008
-
Early stopping of randomized clinical trials for overt efficacy is problematic.
61:241-246.
2008
-
Author reply: the master-question: meta-analyses and stopped-early randomized trials—a problem?.
61:96-98.
2008
-
PsycINFO search strategies identified methodologically sound therapy studies and review articles for use by clinicians and researchers.
61:34-40.
2008
-
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis.
61:64-75.
2008
-
Application of generalizability theory confirmed lower reliability of the standard gamble than the feeling thermometer.
60:1256-1262.
2007
-
Erratum for “A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in complaint patients” [J Clin Epidemiol 59 (2006) 685–696].
60:1203-1203.
2007
-
A comprehensive appropriateness of prescribing questionnaire was validated by nominal consensus group.
60:1022-1028.
2007
-
The standard gamble showed better construct validity than the time trade-off.
60:1029-1033.
2007
-
Systematic reviewers neglect bias that results from trials stopped early for benefit.
60:869-873.
2007
-
Effect sizes can be calculated for studies reporting ranges for outcome variables in systematic reviews.
60:849-852.
2007
-
Composite endpoints in clinical trials: the trees and the forest.
60:660-661.
2007
-
Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns.
60:651-657.
2007
-
Low-back pain definitions in occupational studies were categorized for a meta-analysis using Delphi consensus methods.
60:625.e1-625.e23.
2007
-
Response to paper by Lang A, Edwards N, and Fleiszer A.
60:598-599.
2007
-
A randomized trial of Pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects.
60:456-460.
2007
-
Author reply: the role of pragmatism in publishing.
60:536-536.
2007
-
Studies reporting ROC curves of diagnostic and prediction data can be incorporated into meta-analyses using corresponding odds ratios.
60:530-534.
2007
-
Study of observed and self-reported HRQL in older frail adults found group-level congruence and individual-level differences.
60:502-511.
2007
-
Three methods for minimally important difference: no relationship was found with the net proportion of patients improving.
60:448-455.
2007
-
Hip protectors decrease hip fracture risk in elderly nursing home residents: a Bayesian meta-analysis.
60:336-344.
2007
-
Imputing variance estimates do not alter the conclusions of a meta-analysis with continuous outcomes: a case study of changes in renal function after living kidney donation.
60:228-240.
2007
-
BLISS index for analyzing knee osteoarthritis trials data.
60:124-132.
2007
-
Case selection for statins was similar in two Canadian provinces: BC and Ontario.
60:73-78.
2007
-
EMBASE search strategies achieved high sensitivity and specificity for retrieving methodologically sound systematic reviews.
60:29-33.
2007
-
Exploring design-related bias in clinical studies on receptor genetic polymorphism of hypertension.
60:1.e1-1.e11.
2007
-
Symbols were superior to numbers for presenting strength of recommendations to health care consumers: a randomized trial.
60:1298-1305.
2007
-
Response to Carter et al.: a survey identified publication bias in the secondary literature.
59:1228-1228.
2006
-
Walter O. Spitzer 1937–2006, Co-Editor, Journal of Chronic Disease 1982–1988 and Clinical Epidemiology 1988–1994.
59:1015-1016.
2006
-
Dealing with the media.
59:907-913.
2006
-
Forming research questions.
59:881-886.
2006
-
How to do clinical practice research: a new book and a new series in the Journal of Clinical Epidemiology.
59:873-875.
2006
-
Interrater reliability of measurements of comorbid illness should be reported.
59:926-933.
2006
-
Patients undergoing knee surgery provided accurate ratings of preoperative quality of life and function 2 weeks after surgery.
59:984-993.
2006
-
Preparing a research protocol to improve chances for success.
59:893-899.
2006
-
Preparing reports for publication and responding to reviewers' comments.
59:900-906.
2006
-
Simulated computerized adaptive test for patients with lumbar spine impairments was efficient and produced valid measures of function.
59:947-956.
2006
-
Summaries of findings, descriptions of interventions, and information about adverse effects would make reviews more informative.
59:770-778.
2006
-
A new preference-based analysis for randomized trials can estimate treatment acceptability and effect in compliant patients.
59:685-696.
2006
-
Health Utilities Index mark 3 demonstrated construct validity in a population-based sample with type 2 diabetes.
59:472-477.
2006
-
A gradient of acute gastroenteritis was characterized, to assess risk of long-term health sequelae after drinking bacterial-contaminated water.
59:421-428.
2006
-
Summary measures were a useful alternative for analyzing therapeutic clinical trial data.
59:387-392.
2006
-
“Precision” and “Accuracy”: Two Terms That Are Neither.
59:327-330.
2006
-
New methods give better estimates of changes in diagnostic accuracy when prior information is provided.
59:299-307.
2006
-
Re: In response to the correspondence arising from Twisk and Proper: evaluation of the results of a randomized controlled trial: how to define changes between baseline and follow-up.
59:323-323.
2006
-
Performance measures were necessary to obtain a complete picture of osteoarthritic patients.
59:160-167.
2006
-
Systematic review of qualitative studies exploring parental beliefs and attitudes toward childhood vaccination identifies common barriers to vaccination.
58:1081-1088.
2005
-
Systematically reviewing qualitative studies complements survey design: An exploratory study of barriers to paediatric immunisations.
58:1101-1108.
2005
-
Is NNT now the number needed to traumatize?.
58:1075-1076.
2005
-
Concordance between supervised and postal administration of the Mini Asthma Quality of Life Questionnaire (MiniAQLQ) and Asthma Control Questionnaire (ACQ) was very high.
58:809-814.
2005
-
Procedures that assess inconsistency in meta-analyses can assess the likelihood of response bias in multiwave surveys.
58:856-858.
2005
-
An analysis of general medical and specialist journals that endorse CONSORT found that reporting was not enforced consistently.
58:662-667.
2005
-
The problem of imperfect reference standards.
58:649-650.
2005
-
Simulated computerized adaptive tests for measuring functional status were efficient with good discriminant validity in patients with hip, knee, or foot/ankle impairments.
58:629-638.
2005
-
The standard gamble demonstrated lower reliability than the feeling thermometer.
58:458-465.
2005
-
The standard gamble demonstrated lower reliability than the feeling thermometer.
58:458-465.
2005
-
Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of a survey.
58:291-303.
2005
-
A cohort study found the RAND-12 and Health Utilities Index Mark 3 demonstrated construct validity in high-risk primary care patients.
58:138-141.
2005
-
Electronic mail was not better than postal mail for surveying residents and faculty.
58:425-429.
2005
-
An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methods.
57:1232-1236.
2004
-
Health-related quality of life in women with polycystic ovary syndrome, a self-administered questionnaire, was validated.
57:1279-1287.
2004
-
The number needed to treat (NNT) can be adjusted for bias when the outcome is measured with error.
57:1244-1252.
2004
-
Condition-specific Western Ontario McMaster Osteoarthritis Index was not superior to region-specific Lower Extremity Functional Scale at detecting change.
57:1025-1032.
2004
-
Comment on the comparison of test-retest reliabilities for 2-day and 2-week intervals.
57:993-994.
2004
-
Goodbye, number needed to treat?.
57:219-219.
2004
-
Clinimetrics vs. psychometrics: an unnecessary distinction.
56:1142-1145.
2003
-
Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction.
56:1170-1176.
2003
-
Test development: two-sided coin or one-sided Möbius strip?.
56:1148-1149.
2003
-
Is the health utilities index responsive in total hip arthroplasty patients?.
56:1046-1054.
2003
-
Should meta-analysts search Embase in addition to Medline?.
56:943-955.
2003
-
Comparative responsiveness of generic and specific quality-of-life instruments.
56:52-60.
2003
-
A critical look at transition ratings.
55:900-908.
2002
-
Patient versus injury factors as predictors of pain and disability six months after a distal radius fracture.
55:849-854.
2002
-
Assessing the quality of drug detailing.
55:825-832.
2002
-
In the dark The reporting of blinding status in randomized controlled trials.
55:787-790.
2002
-
Response.
55:532-532.
2002
-
Response.
55:424-425.
2002
-
Response.
55:103-103.
2002
-
Problems of HRQL assessment.
54:1081-1085.
2001
-
Hoehler's adjusted kappa is equivalent to Yule's Y.
54:1072-1072.
2001
-
Establishing the minimal number of items for a responsive, valid, health-related quality of life instrument.
54:571-579.
2001
-
The randomized placebo-phase design for clinical trials.
54:550-557.
2001
-
Sources of heterogeneity in the meta-analysis of observational studies The example of SIDS and sleeping position.
54:440-447.
2001
-
When should an effective treatment be used?.
54:253-262.
2001
-
Discrepancies among megatrials.
53:1193-1199.
2000
-
Choice of effect measure for epidemiological data.
53:931-939.
2000
-
Do potential patients prefer tissue plasminogen activator (TPA) over streptokinase (SK)?.
53:888-894.
2000
-
Randomized trials versus observational studies in adolescent pregnancy prevention.
53:167-174.
2000
-
Lessons learned from enrollment in the BEST study—A multicenter, randomized trial of group psychosocial support in metastatic breast cancer.
53:47-55.
2000
-
A Comparison of Model-Building Strategies for Lower Respiratory Tract Infection in Long-Term Care.
52:1239-1248.
1999
-
Are Health States “Timeless”? The Case of the Standard Gamble Method.
52:1047-1053.
1999
-
Comparison of Open and Closed Questionnaire Formats in Obtaining Demographic Information From Canadian General Internists.
52:997-1005.
1999
-
Meta-Analysis of Diagnostic Tests With Imperfect Reference Standards.
52:943-951.
1999
-
Effect of unequal treatment allocation on sample sizes that account for early stopping in clinical trials: A group sequential approach.
52:38s.
1999
-
Generic and Specific Measurement of Health-Related Quality of Life in a Clinical Trial of Respiratory Rehabilitation.
52:187-192.
1999
-
Selective Opportunistic Screening for Hypercholesterolemia in Primary Care Practice.
51:817-825.
1998
-
Valuing Outcomes in Health Care.
51:667-676.
1998
-
Choice of outcome measure in research synthesis of clinical trials.
51:S28-S28.
1998
-
Methodological problems in the retrospective computation of responsiveness to change: The lesson of Cronbach.
50:869-879.
1997
-
Cost-Benefit Analyses in the Health-Care Literature: Don't Judge a Study by Its Label.
50:813-822.
1997
-
The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials.
50:683-691.
1997
-
Clinical impact versus factor analysis for quality of life questionnaire construction.
50:233-238.
1997
-
Does it matter whom and how you ask? Inter- and intra-rater agreement in the Ontario Health Survey.
50:127-135.
1997
-
A cross-cultural decision instrument for screening mammography.
50:s42.
1997
-
Assessing the minimal important difference in symptoms: A comparison of two techniques.
49:1215-1219.
1996
-
On the debate over methods for estimating the clinically important difference.
49:1223-1224.
1996
-
Response.
49:1206-1206.
1996
-
Assessing reproducibility of enzyme-linked immunosorbent assay serologic tests.
49:1075-1075.
1996
-
Response.
49:1075-1077.
1996
-
A new measure of parent satisfaction with medical care provided in the neonatal intensive care unit.
49:313-318.
1996
-
Measuring patient and relative satisfaction with level or aggressiveness of care and involvement in care decisions in the context of life threatening illness.
48:1215-1224.
1995
-
Methodological issues in assessing reproducibility—A comparative study of various indices of reproducibility applied to repeat ELISA serologic tests for Lyme disease.
48:1123-1132.
1995
-
Medicine, practice and guidelines: The uneasy juncture of science and art.
48:875-880.
1995
-
Use of certainty of opinion data to enhance clinical decision making.
48:897-902.
1995
-
Recall bias in case-control studies: An empirical analysis and theoretical framework.
48:245-254.
1995
-
Methodologic guidelines for systematic reviews of randomized control trials in health care from the potsdam consultation on meta-analysis.
48:167-171.
1995
-
Dissent The professional meta-analyst: An evolutionary advantage.
47:1327-1329.
1994
-
Quality of life after myocardial infarction.
47:1287-1296.
1994
-
Determining a minimal important change in a disease-specific quality of life questionnaire.
47:81-87.
1994
-
Measuring quality of life in the frail elderly.
46:1433-1444.
1993
-
Presentation Preoperative HIV testing: Is it less expensive than universal precautions?.
46:1219-1227.
1993
-
Response Evidence-based vs emotion-based medical decision-making: Routine preoperative HIV testing vs universal precautions.
46:1233-1236.
1993
-
An index of scientific quality for health reports in the lay press.
46:987-1001.
1993
-
Dissent more informative Abstracts: Current status and evaluation.
46:595-597.
1993
-
Interviewer versus self-administered questionnaires in developing a disease-specific, health-related quality of life instrument for asthma.
46:529-534.
1993
-
Can severity of symptoms be used as an outcome measure in trials of non-ulcer dyspepsia and helicobacter pylori associated gastritis?.
46:273-279.
1993
-
A profile of users of specialty pain clinic services: Predictors of use and cost estimates.
45:1399-1415.
1992
-
Measuring health status: What are the necessary measurement properties?.
45:1341-1345.
1992
-
Response A methodologic framework for health status measures: Clarity or oversimplification?.
45:1353-1355.
1992
-
Acute low back pain and economics of therapy: The iterative loop approach.
45:301-311.
1992
-
Agreement among reviewers of review articles.
44:91-98.
1991
-
Pharmacoepidemiology as a focus for clinical epidemiology in developing countries.
45:101-105.
1991
-
Presentation structured abstracts of proposals for clinical and epidemiological studies.
44:731-737.
1991
-
Reliability of interviewer and subject assessments of nevus counts in a study of melanoma.
44:633-640.
1991
-
Repeated serum and urinary androgen measurements in premenopausal and postmenopausal women.
44:1055-1061.
1991
-
Response to Dr Deeg.
44:1122-1123.
1991
-
Statistical significance and fragility criteria for assessing a difference of two proportions.
44:1373-1378.
1991
-
Structured abstracts versus unstructured abstractions.
44:741-742.
1991
-
The international clinical epidemiology network (inclen): A progress report.
44:579-589.
1991
-
Validation of an index of the quality of review articles.
44:1271-1278.
1991
-
A comparison of multivariable mathematical methods for predicting survival-I. Introduction, rationale, and general strategy.
43:339-347.
1990
-
A comparison of multivariable mathematical methods for predicting survival-III. Accuracy of predictions in generating and challenge sets.
43:361-372.
1990
-
A comparison of multivariable mathematical methods for predicting survival—II. Statistical selection of prognostic variables.
43:349-359.
1990
-
Assessment of observer variation in measuring the radiographic vertebral index in patients with multiple myeloma.
43:833-840.
1990
-
Clinical rounds for non-clinicians: Some impressions.
43:613-618.
1990
-
Measuring quality of life in cardiac spouses.
43:481-487.
1990
-
Obesity and mortality in the lipid research clinics program follow-up study.
43:743-752.
1990
-
Prognostic value of prolonged ventricular repolarization following myocardial infarction: The BHAT experience.
43:167-172.
1990
-
Recall bias in epidemiologic studies.
43:1431-1432.
1990
-
Issues in the use of change scores in randomized trials.
42:1097-1105.
1989
-
Meta-analysis in medicine Where we are and where we want to go.
42:35-44.
1989
-
Responsiveness and validity in health status measurement: A clarification.
42:403-408.
1989
-
Should study subjects see their previous responses: Data from a randomized control trial.
42:913-920.
1989
-
Simultaneous interval estimates of the odds ratio in studies with two or more comparisons.
42:427-434.
1989
-
The unproven utility of the preoperative urinalysis: Economic evaluation.
42:1185-1192.
1989
-
A comparison of physician and patient reports of pap smear histories.
41:401-410.
1988
-
A rEAPPRAISAL OF THE KAPPA COEFFICIENT.
41:949-958.
1988
-
Estimation of test error rates, disease prevalence and relative risk from misclassified data: a review.
41:923-937.
1988
-
Measurement of actions of care-providers in long-term care.
41:793-802.
1988
-
Measuring the wellbeing of family caregivers using the time trade-off technique.
41:475-482.
1988
-
Response Kappa and the concept of independent errors.
41:969-970.
1988
-
Strengths and limitations of the Apgar score: A critical appraisal.
41:843-850.
1988
-
The contribution of a non-invasive test to clinical care The impact of echocardiography on diagnosis, management and patient anxiety.
41:151-161.
1988
-
A comparison of Likert and visual analogue scales for measuring change in function.
40:1129-1133.
1987
-
Measuring change over time: Assessing the usefulness of evaluative instruments.
40:171-178.
1987
-
Utility approach to measuring health-related quality of life.
40:593-600.
1987
-
An analysis of Berkson's bias in case-control studies.
39:495-504.
1986
-
An epidemiological description of physical, social and psychological problems in multiple sclerosis.
39:305-310.
1986
-
Case-control studies for the evaluation of screening.
39:399-405.
1986
-
Construction of social value or utility-based health indices: The usefulness of factorial experimental design plans.
39:643-651.
1986
-
The problem of home management in the estimation of the incidence of acute myocardial infarction from hospital records.
39:683-686.
1986
-
The role of before-after studies of therapeutic impact in the evaluation of diagnostic technologies.
39:295-304.
1986
-
A methodological framework for assessing health indices.
38:27-36.
1985
-
How should we measure function in patients with chronic heart and lung disease?.
38:517-524.
1985
-
Hypothesis testing and sample size for bivariate binomial response in the comparison of two groups.
38:603-608.
1985
-
Methodologic problems in clinical trials in heart failure.
38:353-363.
1985
-
Should study subjects see their previous responses?.
38:1003-1007.
1985
-
The measurement iterative loop: A framework for the critical appraisal of need, benefits and costs of health interventions.
38:339-351.
1985
-
Commentary on “use of dual responses to increase validity of case-control studies”.
37:137-139.
1984
-
Determining causation—A case study: Adrenocorticosteroids and osteoporosis.
37:343-352.
1984
-
Effects of labelling on income, work and social function among hypertensive employees.
37:417-423.
1984
-
Further comment on the dual report dispute.
37:143-143.
1984
-
Labelling in hypertension: A review of the behavioural and psychological consequences.
37:933-942.
1984
-
The impact of a psychosocial support program on survival with breast cancer: The importance of selection bias in program evaluation.
37:273-282.
1984
-
Relative efficiency in survival analysis.
36:183-192.
1983
-
The modified sphygmomanometer—An instrument to measure muscle strength: A validation study.
34:353-361.
1981
-
Berkson's bias and its control in epidemiologic studies.
33:721-725.
1980
-
Urolithiasis—a study of drinking water hardness and genetic factors.
33:727-731.
1980
-
An empirical demonstration of Berkson's bias.
31:119-128.
1978
-
The utility of different health states as perceived by the general public.
31:697-704.
1978
-
Clustering during childhood of multiple sclerosis patients.
30:217-224.
1977
has subject area
Identity
International Standard Serial Number (ISSN)
-
0021-9681
-
0895-4356
-
0959-8138
Electronic International Standard Serial Number (EISSN)